Canada markets close in 27 minutes

Aion Therapeutic Inc. (AION.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.01500.0000 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Previous Close0.0150
Open0.0150
Bid0.0100 x N/A
Ask0.0150 x N/A
Day's Range0.0150 - 0.0150
52 Week Range0.0100 - 0.0800
Volume50,000
Avg. Volume65,679
Market Cap2.127M
Beta (5Y Monthly)0.70
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateSept 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes

    Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer

  • Newsfile

    Aion Therapeutic Files Financials

    Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of the Company has been subject to a management cease trade order (the "MCTO") in respect of the securities of the Company issued by the applicable securities ...

  • CNW Group

    Aion Therapeutic Provides Default Status Update

    Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 14, 2021 and September 28, 2021, the Company is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").